Margarita Nunez
St Petersburg, FLNPI 1780885855
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $4,168 of the $5,042 with a category attached, or 82.7%. 4 manufacturers reported payments, led by Modernatx, Inc. at 48.5% of the total. Reporting peaked in 2023 at $2,730 and has fallen 63.9% since, to $986 in 2025.
Across 25 payments — averaging $201.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$2K
- Genentech USA, Inc.$2K
- Boehringer Ingelheim$986
- Merck$54
Across 110 payments — averaging $3125.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$283K
- Boehringer Ingelheim International GmbH$14K
- Janssen Research & Development, LLC$13K
- Genentech, Inc.$10K
- AstraZeneca$10K
- AbbVie$5K
- plus $9K from 3 others
What the payments were for
- Travel & lodging$4,16883%
- Food & beverage$87417%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 12 | $2,443 |
| Genentech USA, Inc. | 5 | $1,559 |
| Boehringer Ingelheim | 6 | $986 |
| Merck | 2 | $54 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.